Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Cantargia AB today announced that its research platform CANxx has progressed with the start of a drug development project, CAN10. The project originates from inhibition of three inflammatory cytokine systems (IL-1, IL-33 and IL-36) by antibody targeting of interleukin 1 receptor accessory protein (IL1RAP). The project will focus on unmet medical need in systemic sclerosis and myocarditis. The goal is to initiate clinical development late 2021.Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The lead project CAN04 is in phase